Novo Nordisk
NVO
1,786 hedge funds and large institutions have $39.7B invested in Novo Nordisk in 2024 Q3 according to their latest regulatory filings, with 146 funds opening new positions, 708 increasing their positions, 646 reducing their positions, and 205 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 708 | Existing positions reduced: 646
0.04% less ownership
Funds ownership: 7.53% → 7.49% (-0.04%)
4% less funds holding
Funds holding: 1,864 → 1,786 (-78)
17% less capital invested
Capital invested by funds: $47.9B → $39.7B (-$8.22B)
29% less first-time investments, than exits
New positions opened: 146 | Existing positions closed: 205
30% less funds holding in top 10
Funds holding in top 10: 90 → 63 (-27)
32% less call options, than puts
Call options by funds: $791M | Put options by funds: $1.16B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$430M |
| 2 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
+$128M |
| 3 |
D.E. Shaw & Co
New York
|
+$115M |
| 4 |
MIF
Mediolanum International Funds
Dublin 1,
Ireland
|
+$110M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$82.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$208M |
| 2 |
Millennium Management
New York
|
-$194M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$156M |
| 4 |
Jennison Associates
New York
|
-$137M |
| 5 |
Renaissance Technologies
New York
|
-$130M |
NVO Hedge Fund Activity: Q3 2024 in Review
1,786 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2024, worth a combined $39.7B — down 17% from $47.9B a quarter earlier.
Sellers outnumbered buyers: 205 funds closed out of NVO and 146 opened new positions — a net loss of 59 holders — while 646 trimmed existing stakes and 708 added.
The largest buyer was GQG Partners, adding an estimated $430M. The largest seller was Fidelity Investments, cutting an estimated $208M.
- 1,786 institutional investors held Novo Nordisk (NVO) as of Q3 2024, down from 1,864 in Q2 2024.
- Funds reported $39.7B of Novo Nordisk stock for Q3 2024, down 17% quarter-over-quarter.
- 146 funds opened new Novo Nordisk positions in Q3 2024 and 205 closed out, a net change of -59 holders.
- The largest Novo Nordisk buyer in Q3 2024 was GQG Partners, an estimated $430M added.
- The largest Novo Nordisk seller in Q3 2024 was Fidelity Investments, an estimated $208M sold.
Based on aggregated 13F filings for Q3 2024.